Generex Biotechnology's Subsidiary Enters into Collaboration to Develop SARS Vaccine
TORONTO -- Generex Biotechnology
Corporation announces that it has entered into a
collaboration with Dr. Bing Sun of the Chinese Academy of Science (IBC) in
Shanghai to develop a SARS vaccine.
Sun has done pioneering work isolating SARS genes which can be used in a DNA vaccine. Antigen Express, Generex's subsidiary, has developed proprietary and patented technologies to enhance the potency of DNA vaccines. Together they seek to create an effective DNA vaccine for protection against SARS infections.
Antigen Express' technology focuses on modulating immune responses
mediated by T helper cells, a class of lymphocytes that plays many roles in
the immune system, both enhancing and suppressing immune responses. T helper
cells are essential for obtaining both robust and long lasting responses
against infections, cancer and against specific antigens which are encoded in
DNA vaccines.
"The heart of the Antigen Express technology platform is controlling
antigen presentation by MHC class II molecules to elicit better T helper cell
activation," explained Dr. Robert Humphreys, founder of Antigen Express. "In
the case of DNA vaccines, the Antigen Express component used with the DNA
vaccine inhibits expression of the MHC class II-associated invariant chain (Ii
protein). This protein normally prevents MHC class II molecules from
presenting intracellularly synthesized antigens, such as those encoded in DNA
vaccines, in a manner that adequately stimulates T helper cells."
The SARS genes to be used in the DNA vaccine will be supplied by Dr. Sun.
His leading studies have helped to characterize the best SARS genes to use for
stimulation of an immune response.
Antigen Express has received several SBIR grants from the National
Institutes for Allergy and Infectious Diseases and the National Cancer
Institute, to apply this technology in DNA vaccine projects for cancer and
infectious diseases.
"We are pleased to be initiating serious efforts in SARS vaccine
development using the proprietary technologies pioneered at Antigen Express,"
said Anna Gluskin, CEO of Generex. "The SARS virus is still a problem in the
world today and therefore an important indication for demonstrating the
potential of T helper stimulating technologies."
Generex is engaged in the research and development of drug delivery
systems and technology. To date, it has focused on developing a platform
technology for the buccal delivery -- delivery to the oral cavity for
absorption through the inner mouth mucosa -- of drugs that historically have
been administered only by injection. Generex's buccal delivery technology has
application to a large number of drugs. Generex acquired Antigen Express in
August. 2003. The core platform technologies of Antigen Express comprise
immunotherapeutics for the treatment of malignant, infectious, allergic, and
autoimmune diseases.
Source: Generex Biotechnology Corporation
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
